Chimerix, Inc. (CMRX) CEO Mike Sherman on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/25/20
Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats MeetingGlobeNewsWire • 01/29/20
Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual MeetingGlobeNewsWire • 12/10/19
Chimerix's (CMRX) CEO Michael Sherman on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for BrincidofovirGlobeNewsWire • 09/30/19
Chimerix (CMRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 08/07/19
Chimerix's (CMRX) CEO Mark Iwicki on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/09/19
Will Chimerix (CMRX) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/29/19